| Similar Articles |
|---|
 |
Chemistry World
June 21, 2006
Katharine Sanderson |
Peptide Agent Tracks Angiogenesis A molecular imaging agent that can track the progress of tumour growth is about to be trialled by GE Healthcare.   |
Managed Care
January 2004
Thomas Morrow |
Choking Off a Tumor's Blood Supply Angiogenesis blockade is a 30-year-old concept, but it will soon make the leap from lab bench to pharmacy shelf. |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
Chemistry World
July 3, 2015
Andy Extance |
Pharma queues up for checkpoint inhibitor collaborations Amid fierce rivalries over the latest generation of cancer treatments, drug makers have been weaving a complex web of collaborations on combination therapies spanning much of the pharmaceutical industry. |
Chemistry World
September 2007
Derek Lowe |
Column: In the Pipeline Will Phase Zero trials actually help drug development? |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
Chemistry World
September 10, 2008
Simon Hadlington |
Failed anxiety drug could treat cancer Scientists believe they have solved the mystery of how a drug originally developed for treating anxiety can kill cancer cells. |
The Motley Fool
April 19, 2004
Charly Travers |
4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
Pharmaceutical Executive
December 1, 2005
Ron Feemster |
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
The Motley Fool
June 17, 2010
Luke Timmerman |
Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials. |
The Motley Fool
November 2, 2004
Charly Travers |
Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer. |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
Chemistry World
August 11, 2011
Simon Hadlington |
Getting to the Core of a Tumour for Drug Study Researchers have devised new a way to test how well drugs penetrate the low-oxygen core of solid tumors. |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
Chemistry World
June 2011 |
Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress |
Chemistry World
July 28, 2006
Tom Westgate |
Radioactive Scorpion Venom Stings Brain Tumours Scorpion venom carries a nasty sting for brain tumour cells. A peptide based on chlorotoxin, found in the venom of the Giant Yellow Israeli Scorpion, has been used to target glioma, a particularly aggressive form of brain tumour. |
Chemistry World
June 11, 2007
Victoria Gill |
Cancer Therapy Targets Bad Blood Tumors have a nasty habit of quickly developing their own blood supply in order to feed their rapid growth. Now, researchers have discovered a set of biological markers that distinguish tumor-specific blood vessels from normal, healthy vasculature. |
Chemistry World
January 17, 2011
Laura Howes |
Nanoparticle divides to conquer Scientists have made a nanoparticle that breaks up into smaller units once it reaches its target, allowing it to penetrate deeper into tumour tissue and deliver treatment more effectively. |
Chemistry World
June 15, 2007
Lionel Milgrom |
Electrochemical Screening for Anti-Cancer Drugs A test that predicts an individual cancer patient's response to different drugs is about to enter clinical trials, developers have announced. The chances of successful treatment will increase, they predict, while costs will decrease. |
Chemistry World
April 10, 2008
Sarah Houlton |
Radiotherapy Side-Effects Suppressed A new drug being developed by scientists at Cleveland BioLabs (CBLI) in the US may hold the key to protecting healthy cells from the effects of radiotherapy during cancer treatment. |
Chemistry World
November 23, 2006
Victoria Gill |
Bacteria That Help Fight Cancer Scientists have given a new meaning to the term `friendly bacteria' by discovering a bacterial protein that helps treat cancer. |
Chemistry World
May 26, 2011
Mike Brown |
Ibuprofen: anticancer drug Scientists in the UK have moved a step closer to understanding how ibuprofen could help treat cancer. |
Chemistry World
March 4, 2011
Elinor Richards |
Laser treatment for late-stage cancer Scientists from China, the US and Peru claim to have successfully treated late-stage breast cancer patients using laser immunotherapy to stimulate patients' own immune systems to fight the cancer. |
Chemistry World
June 4, 2015
Thadchajini Retneswaran |
Microfluidic approach to personalised cancer treatment US scientists have developed an innovative microfluidic assay that can accurately predict how patients with a certain type of blood cancer will respond to an anticancer drug. |
Chemistry World
January 17, 2008
Lewis Brindley |
Nanomachines to Treat Cancer Scientists at the University of California-Los Angeles (UCLA) have signed a deal with a private investment firm to develop and market 'nanomachines' to treat cancer. |
Reactive Reports
Issue 56
Jeffrey Krise |
A Basic Approach to Chemotherapy Chemists have found a way to attack malignant cells with an anticancer drug, while sparing healthy cells. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
March 14, 2008
Brian Orelli |
Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet? |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Chemistry World
July 22, 2013
Kirsty Muirhead |
Circulating cancer cells spiral towards separation A new biochip developed by researchers in Singapore can isolate tumor cells from blood samples, and may one day be an alternative to more invasive methods for tracking later stage cancers. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Chemistry World
June 4, 2008
John Bonner |
Fireflies make light work of tumours Cancer researchers can see how effective new chemotherapy drugs are at destroying tumours by using the light that causes fireflies to glow in the dark. |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
November 30, 2007
Brian Orelli |
Clinical Trial Failures Don't Bother These Companies Contract research organizations, outsourcing companies hired by pharmaceutical and biotech companies to run pre-clinical tests and clinical trials for them, succeed even when drugs fail, and more work may be coming their way. |
Chemistry World
November 21, 2006
Victoria Gill |
Side-Effect-Free Chemotherapy Scientists have now developed an enzyme with the potential to eliminate the extreme fatigue, sickness and hair loss that result from this cell damage and strike fear into the hearts of cancer patients. |
Pharmaceutical Executive
October 1, 2011
William Looney |
Curative Powers of Collaboration Napoleone Ferrara's career in medicine is an illustration of the maxim that stretching the boundaries of science is a leap in the dark. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
Chemistry World
June 3, 2011
Jennifer Newton |
Across the barrier for tumor imaging A probe that can cross the blood-brain barrier to allow high sensitivity brain tumor imaging has been made by Chinese scientists. |
Chemistry World
May 28, 2008
Mark Peplow |
Cancer research gets collaborative funding boost In an effort to crack some of the biggest problems in cancer drug discovery, Cancer Research UK has launched a unique funding program that promises to help bridge the gap between fundamental research and big pharma pipelines. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
Chemistry World
November 11, 2015
Maria Burke |
Viral cancer therapy approved in the US The first virus therapy to target cancer has been approved in the US. Its main target will be melanoma, the most aggressive form of skin cancer. |
Chemistry World
April 11, 2006
Jon Evans |
Nanotechnology Tackles Chemotherapy Chemists and medical researchers have developed nanoparticles that target chemotherapy drugs directly at tumours. The researchers claim that the same technique could be used to develop nanoparticle-based treatments for a wide range of other diseases. |
Chemistry World
January 8, 2007
Michael Gross |
Nano-Clots Target Tumours Researchers have created nanoparticles that form clots within the blood vessels of tumors. They hope that with further improvements these could be used either to starve tumors or to target them with cytotoxic drugs. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
